Vertex Pharmaceuticals Inc (VRTX)

Debt-to-capital ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 17,580,400 16,512,800 15,470,200 14,432,300 13,912,700 13,029,600 11,933,500 10,907,000 10,100,000 9,530,800 9,196,400 8,980,300 8,686,800 8,133,470 7,519,240 6,461,650 6,085,200 5,253,390 5,069,960 4,723,310
Debt-to-capital ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $17,580,400K)
= 0.00

The debt-to-capital ratio of Vertex Pharmaceuticals, Inc. has shown a relatively stable trend over the past eight quarters. The ratio has been consistently low, ranging between 0.02 to 0.04 during this period. This indicates that the company has a conservative approach to debt financing, relying more on equity to fund its operations and growth. A low debt-to-capital ratio suggests that Vertex Pharmaceuticals has a strong financial position with a lower level of debt in relation to its total capital. Overall, the company's consistent low debt-to-capital ratio reflects sound financial management and a relatively low risk of financial distress related to debt obligations.


Peer comparison

Dec 31, 2023


See also:

Vertex Pharmaceuticals Inc Debt to Capital (Quarterly Data)